US 10,888,530 B2
Implantable drug delivery compositions and methods of use thereof
John Schwartz, Newton, MA (US); and Aaron Henry Colby, Concord, MA (US)
Assigned to AcuityBio Corporation, Newtonville, MA (US)
Filed by AcuityBio Corporation, Newton, MA (US)
Filed on Dec. 18, 2017, as Appl. No. 15/845,902.
Application 15/845,902 is a continuation of application No. PCT/US2016/038080, filed on Jun. 17, 2016.
Claims priority of provisional application 62/181,707, filed on Jun. 18, 2015.
Prior Publication US 2018/0193282 A1, Jul. 12, 2018
Int. Cl. A61K 9/00 (2006.01); A61L 31/16 (2006.01); A61P 35/00 (2006.01); A61K 9/70 (2006.01); A61L 27/36 (2006.01); A61L 31/10 (2006.01); A61L 31/14 (2006.01); A61L 27/54 (2006.01); A61L 27/56 (2006.01); A61L 27/34 (2006.01); A61L 27/18 (2006.01); A61L 31/06 (2006.01); A61L 27/58 (2006.01); A61K 31/337 (2006.01); A61K 47/34 (2017.01); A61K 47/46 (2006.01)
CPC A61K 9/70 (2013.01) [A61K 9/007 (2013.01); A61K 9/0024 (2013.01); A61K 31/337 (2013.01); A61K 47/34 (2013.01); A61K 47/46 (2013.01); A61L 27/18 (2013.01); A61L 27/34 (2013.01); A61L 27/3604 (2013.01); A61L 27/54 (2013.01); A61L 27/56 (2013.01); A61L 27/58 (2013.01); A61L 31/06 (2013.01); A61L 31/10 (2013.01); A61L 31/148 (2013.01); A61L 31/16 (2013.01); A61P 35/00 (2018.01); A61L 2300/416 (2013.01); A61L 2300/602 (2013.01)] 8 Claims
 
1. An implantable composition comprising an acellular collagen matrix together with poly(lactic-co-glycolic acid) copolymer (PLGA), polyethylene glycol (PEG) 8000 and paclitaxel, wherein:
the PLGA has a molecular weight ranging from about 20,000 g/mol to about 250,000 g/mol;
the PLGA has a lactide/glycolide molar ratio of about 40:60 to about 60:40;
the paclitaxel is present in an amount of 50% by weight or less based on the total weight of the PLGA and PEG 8000; and
the PEG 8000 is present in an amount of between about 5% by weight to about 35% by weight based on the total weight of the PLGA and the paclitaxel.